Related Experiment Videos
Active and passive immunization against HIV type 1 infection in chimpanzees
K K Murthy1, E K Cobb, S R Rouse
1Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas 78228-0147, USA.
AIDS Research and Human Retroviruses
|November 14, 1998
Summary
Preventing human immunodeficiency virus (HIV) infection is crucial. Research in chimpanzees shows that neutralizing antibodies are key to blocking primary HIV infection, guiding future vaccine development.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Developing a human immunodeficiency virus (HIV) vaccine remains a global health priority.
- Chimpanzees serve as a critical animal model for preclinical HIV vaccine evaluation.
- Understanding immune responses is vital for designing effective HIV prevention strategies.
Purpose of the Study:
- To assess the safety and efficacy of various HIV vaccine candidates in a preclinical setting.
- To identify immune correlates of protection against HIV infection in the chimpanzee model.
- To evaluate the role of different immunization strategies in preventing HIV acquisition.
Main Methods:
- Over 25 active and passive immunization strategies were tested in chimpanzees.
- Vaccine efficacy was determined by challenging vaccinated animals with cell-free or cell-associated HIV via intravenous or mucosal routes.
- Immune responses, particularly antibody production, were analyzed post-challenge.
Main Results:
- The chimpanzee model has been instrumental in evaluating numerous HIV vaccine candidates.
- Vaccine efficacy was assessed based on protection against primary HIV infection following various challenge methods.
- A significant finding across studies indicates a major role for neutralizing antibodies in preventing initial HIV infection.
Conclusions:
- Neutralizing antibodies are strongly implicated as a primary mechanism for preventing HIV infection.
- The chimpanzee model provides valuable insights into the correlates of protection for HIV vaccines.
- Further research should focus on strategies that elicit robust neutralizing antibody responses.